Identification of a complement receptor 1 peptide for inhibition of immune hemolysis

Biochemical and Biophysical Research Communications

Volumn 353, Issue 2, 2007, Pages 363-368

  Yu, Jin ^a   Heck, Susanne ^a   Debnath, Asim ^a   Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

C3a; C3b; CD35; Complement inhibition; Complement receptor 1; CR1 peptides; Hemolysis; Homology modeling; Mouse model; Transfusion reactions; Transfusion therapy

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; GLUTAMYLCYSTEINYLARGINYLPROLYLGLYCYLTYROSYLSERYLGLYCYLARGINYLPROLYL PHENYLALANYLSERYLISOLEUCYLISOLEUCYLCYSTEINYLLEUCYLLYSYLASPARAGINYLSERYLVALYL TRYPTOPHYLTHREONYLGLYCYLALANYLLYSYLASPARTYLARGINYLCYSTEINYLARGINYLARGININE; PEPTIDE DERIVATIVE; SERYLCYSTEINYLTHREONYLLYSYLGLYCYLTYROSYLARGINYLLEUCYLISOLEUCYLGLYCYL SERYLSERYLSERYLALANYLTHREONYLSERYLISOLEUCYLISOLEUCYLSERYLGLYCYLASPARTYL THREONYLVALYLISOLEUCYLTRYPTOPHYLASPARTYLASPARAGINYLGLUTAMYLTHREONYLPROLYL ISOLEUCYLCYSTEINYLASPARTYLARGININE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL SURVIVAL; COMPLEMENT INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COMPUTER SIMULATION; HEMOLYSIS; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33845910927     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.020     Document Type: Article

References (29)

1. Petz L.D., and Garratty G. Immune Hemolytic Anemias (2004), Churchill Livingston
2. Mollnes T.E., and Kirschfink M. Strategies of therapeutic complement inhibition. Mol. Immunol. 43 (2006) 107-121
3. Hourcade D., Liszewski M.K., Krych-Goldberg M., and Atkinson J.P. Functional domains, structural variations and pathogen interactions of MCP, DAF, and CR1. Immunopharmacology 49 (2000) 103-116
4. Iida K., and Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 153 (1981) 1138-1150
5. Fearon D.T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl. Acad. Sci. USA 76 (1979) 5867-5871
6. Ross G.D. Complement receptor type 1. Curr. Top. Microbiol. Immunol. 178 (1992) 31-44
7. Makrides S.C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50 (1998) 59-87
8. Weisman H.F., Bartow T., Leppo M.K., Marsh Jr. H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., and Fearon D.T. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990) 146-151
9. Perry G.J., Eisenberg P.R., Zimmerman J.I., and Levin J. Phase I safety trial of soluble complement receptor 1 (TP10) in acute myocardial infarction. J. Am. Coll. Cardiol. 31 (1998) 411A
10. Zamora M.R., Davis R.D., Keshavjee S.H., Schulman L., Levin J., Ryan U., and Patterson G.A. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 116 (1999) 46S
11. Zimmerman J.L., Dellinger R.P., Straube R.C., and Levin J.L. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 28 (2000) 3149-3154
12. Yazdanbakhsh K., Kang S., Tamasauskas D., Sung D., and Scaradavou A. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 101 (2003) 5046-5052
13. Yazdanbakhsh K., and Scaradavou A. CR1-based inhibitors for prevention of complement-mediated immune hemolysis. Drug News Perspect. 17 (2004) 314-320
14. Klickstein L.B., Bartow T.J., Miletic V., Rabson L.D., Smith J.A., and Fearon D.T. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168 (1988) 1699-1717
15. Mqadmi A., Abdullah Y., and Yazdanbakhsh K. Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction. Transfusion 45 (2005) 234-244
16. Krych-Goldberg M., Hauhart R.E., Subramanian V.B., Yurcisin B.M., Crimmins D.L., Hourcade D.E., and Atkinson J.P. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J. Biol. Chem. 274 (1999) 31160-31168
17. Krych M., Hourcade D., and Atkinson J.P. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc. Natl. Acad. Sci. USA 88 (1991) 4353-4357
18. Krych M., Clemenza L., Howdeshell D., Hauhart R., Hourcade D., and Atkinson J.P. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J. Biol. Chem. 269 (1994) 13273-13278
19. Krych M., Hauhart R., and Atkinson J.P. Structure-function analysis of the active sites of complement receptor type 1. J. Biol. Chem. 273 (1998) 8623-8629
20. Krych-Goldberg M., Hauhart R.E., Porzukowiak T., and Atkinson J.P. Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors. J. Immunol. 175 (2005) 4528-4535
21. Smith B.O., Mallin R.L., Krych-Goldberg M., Wang X., Hauhart R.E., Bromek K., Uhrin D., Atkinson J.P., and Barlow P.N. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 108 (2002) 769-780
22. Lukacik P., Roversi P., White J., Esser D., Smith G.P., Billington J., Williams P.A., Rudd P.M., Wormald M.R., Harvey D.J., Crispin M.D., Radcliffe C.M., Dwek R.A., Evans D.J., Morgan B.P., Smith R.A., and Lea S.M. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci. USA 101 (2004) 1279-1284
23. Sali A., and Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
24. Laskowski R.A., Moss D.S., and Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231 (1993) 1049-1067
25. Issitt P.D. Applied Blood Group Serology (1985), Montgomery Scientific Publications, Miami, FL
26. Kuttner-Kondo L.A., Mitchell L., Hourcade D.E., and Medof M.E. Characterization of the active sites in decay-accelerating factor. J. Immunol. 167 (2001) 2164-2171
27. Werle M., and Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30 (2006) 351-367
28. Seya T., Holers V.M., and Atkinson J.P. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J. Immunol. 135 (1985) 2661-2667
29. Smith R.A. Targeting anticomplement agents. Biochem. Soc. Trans. 30 (2002) 1037-1041